Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Unmet need: CLL patients intolerant to novel therapies

Danielle Brander • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Danielle Brander, MD, Duke University School of Medicine, Durham, NC, discusses the treatment of individuals intolerant to novel therapies and how to achieve the same efficacy through alternative routes. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Danielle Brander

1:49
The management of Richter's transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023
1:13
Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander • 8 Dec 2023
1:46
Managing the side effects associated with BTKi treatment for CLL
Danielle Brander • 8 Dec 2023
1:27
Frontline therapies for treatment naive CLL patients
Danielle Brander • 21 Sep 2019

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals